​»The goal of our research is, within the framework of our research projects, to gain new insights in a systematic and verifiable manner, and thus enable progress in immunotherapy.«​​

Antigen production and antigen presentation of immunocompetent dendrictic cells for tumour vaccination​

Extending ELISPOT diagnostics​

At the IOZK, we assess the success of the dendritic cell vaccine with a modified ELISPOT (Enzyme Linked lmmuno Spot Assay). Diagnostics with the ELISPOT remain the standard method of testing for specific T cells, however, many alternatives or improvements with increased sensitivity are discussed in scientific literature. We want to find out, if extending the currently used ELISPOT can lead to a more conclusive result. In collaboration with Immatics GmbH in Tübingen, we want to test their assay with the ELISPOT from our laboratory. Comparison with further commercially available kits is possible.​

Participating in scientific discussions​

The scientific exchange that takes place at conferences is an important aspect for developing basic research in tumour immunotherapy. For this reason, the researchers of the IOZK Foundation will actively participate at conferences such as the CIMT in Mains and the CICON in Paris.​

his EU-funded PhD project will investigate the effect of our specific tumour vaccine in Glioblastoma multiforme. This is a Marie-Skłodowska-Curie Action with which the Europeran Union wants to support the careers of international and interdisciplinary scientists. These measures are part of Horizon 2020, the European framework programme for research and innovation. The action is named after the Nobel Prize winner Marie Curie. The programme was developed by the European Commission to make a career in the sciences and Europe as a research base more attractive and to improve the pool of European scientists.​

Immunotherapy based on encapsulating oncolytic viruses in nanoparticles​

Publication of research results​

After completion of the projects, the results will be published in scientific literature and online. The newly gained knowledge is made available and will be accessible to all interested.​

RESEARCH PROJECTS 2019–2020

In this project, a collaboration with the Institute for Clinical Immunology at Leipzig University, the aim is to modify tumour antigens to improve antigen presentation to enhance the possible success of a cancer therapy. Tumour-associated tolerance mechanisms can currently be effectively reduced through checkpoint inhibitors. However, how the suitable tumour antigens should be produced is widely discussed in the research community and scientific literature presents many different options. This project will compare different methods of antigen production and test their possible application for the treatment of humans.​

​»The goal of our research is, within the framework of our research projects, to gain new insights in a systematic and verifiable manner, and thus enable progress in immunotherapy.«​​

In this project, a collaboration with the Institute for Clinical Immunology at Leipzig University, the aim is to modify tumour antigens to improve antigen presentation to enhance the possible success of a cancer therapy. Tumour-associated tolerance mechanisms can currently be effectively reduced through checkpoint inhibitors. However, how the suitable tumour antigens should be produced is widely discussed in the research community and scientific literature presents many different options. This project will compare different methods of antigen production and test their possible application for the treatment of humans.​

At the IOZK in Cologne, we assess the success of the dendritic cell vaccine with a modified ELISPOT (Enzyme Linked lmmuno Spot Assay). Diagnostics with the ELISPOT remain the standard method of testing for specific T cells, however, many alternatives or improvements with increased sensitivity are discussed in scientific literature. We want to find out, if extending the currently used ELISPOT can lead to a more conclusive result. In collaboration with Immatics GmbH in Tübingen, we want to test their assay with the ELISPOT from our laboratory. Comparison with further commercially available kits is possible.​

This EU-funded PhD project will investigate the effect of our specific tumour vaccine in Glioblastoma multiforme. This is a Marie-Skłodowska-Curie Action with which the Europeran Union wants to support the careers of international and interdisciplinary scientists. These measures are part of Horizon 2020, the European framework programme for research and innovation. The action is named after the Nobel Prize winner Marie Curie. The programme was developed by the European Commission to make a career in the sciences and Europe as a research base more attractive and to improve the pool of European scientists.​

The scientific exchange that takes place at conferences is an important aspect for developing basic research in tumour immunotherapy. For this reason, the researchers of the IOZK Foundation will actively participate at conferences such as the CIMT in Mains and the CICON in Paris.​

After completion of the projects, the results will be published in scientific literature and online. The newly gained knowledge is made available and will be accessible to all interested.​

de   eng